⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1801007 | 0.78 | — | — | |
| SCHEMBL18631359 | 0.75 | — | — | |
| SCHEMBL18631183 | 0.75 | — | — | |
| SCHEMBL14687475 | 0.73 | — | — | |
| SCHEMBL6524577 | 0.73 | TSHR (0.30) | — | |
| SCHEMBL4902100 | 0.72 | TSHR (0.31) | — | |
| SCHEMBL6555420 | 0.71 | ALDH1A1 (0.39) | — | |
| SCHEMBL12852765 | 0.71 | — | — | |
| SCHEMBL18634138 | 0.69 | FDPS (0.30) | — | |
| SCHEMBL21987152 | 0.69 | ACLY (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250099448-A1 | HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2025-03-27 | — | — | US | disclosed |
| US-20240199587-A1 | HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2024-06-20 | — | — | US | disclosed |
| US-11981661-B2 | Heterocyclic compounds | HOFFMANN-LA ROCHE INC. (US) | 2024-05-14 | — | — | US | disclosed |
| EP-4326714-A1 | HETEROCYCLIC COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2024-02-28 | — | — | EP | disclosed |
| CN-117295726-A | Heterocyclic compounds | 豪夫迈·罗氏有限公司 | 2023-12-26 | — | — | CN | disclosed |
| US-11753397-B2 | Cereblon binders for the degradation of ikaros | C4 THERAPEUTICS, INC. (US) | 2023-09-12 | — | — | US | disclosed |
| US-11753397-B2 | Cereblon binders for the degradation of ikaros | C4 THERAPEUTICS, INC. (US) | 2023-09-12 | — | — | US | disclosed |
| US-11753397-B2 | Cereblon binders for the degradation of ikaros | C4 THERAPEUTICS, INC. (US) | 2023-09-12 | — | — | US | disclosed |
| EP-4208456-A1 | HETEROCYCLIC COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2023-07-12 | — | — | EP | disclosed |
| CN-115989228-A | Heterocyclic compounds | 豪夫迈·罗氏有限公司 | 2023-04-18 | — | — | CN | disclosed |
| EP-0579618-B1 | PYRIDINE- AND IMIDAZOLE-DERIVED AGENTS FOR CARDIOVASCULAR DISEASES | PFIZER LTD (GB) | 1999-10-13 | — | — | EP | disclosed |
| US-5776933-A | Method of inhibiting protease | E. R. SQUIBB & SONS, INC. (US) | 1998-07-07 | — | — | US | disclosed |
| US-5760036-A | ENZYME INHIBITORS OF RETROVIRAL PROTEASE FOR PREVENTION OF AIDS | E. R. SQUIBB & SONS, INC. (US) | 1998-06-02 | — | — | US | disclosed |
| US-5705523-A | THROMBOXANE A2 SYNTHETASE INHIBITORS | PFIZER INC. (US) | 1998-01-06 | — | — | US | disclosed |
| US-5559256-A | Aminediol protease inhibitors | E. R. SQUIBB & SONS, INC. (US) | 1996-09-24 | — | — | US | disclosed |
| CN-1032361-C | Imidazopyridazines, their production and use | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1996-07-24 | — | — | CN | disclosed |
| US-5457118-A | Pyridine derived agents for cardiovascular diseases | PFIZER INC. (US) | 1995-10-10 | — | — | US | disclosed |
| EP-0579618-A1 | PYRIDINE- AND IMIDAZOLE-DERIVED AGENTS FOR CARDIOVASCULAR DISEASES | Pfizer Limited (GB) | 1994-01-26 | — | — | EP | disclosed |
| EP-0580402-A2 | Aminediol protease inhibitors | E.R. SQUIBB & SONS, INC. (US) | 1994-01-26 | — | — | EP | disclosed |
| WO-1992017451-A1 | PYRIDINE- AND IMIDAZOLE-DERIVED AGENTS FOR CARDIOVASCULAR DISEASES | PFIZER LIMITED (GB) | 1992-10-15 | — | — | WO | disclosed |